Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer
Although immune checkpoint inhibitors improve median overall survival in patients with metastatic urothelial cancer (mUC), only a minority of patients benefit from it. Early blood-based response biomarkers may provide a reliable way to assess response weeks before imaging is available, enabling an e...
Main Authors: | Sandra van Wilpe, Victoria Wosika, Laura Ciarloni, Sahar Hosseinian Ehrensberger, Rachel Jeitziner, Paolo Angelino, Tjitske Duiveman-de Boer, Rutger H. T. Koornstra, I. Jolanda M. de Vries, Winald R. Gerritsen, Jack Schalken, Niven Mehra |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/18/4660 |
Similar Items
-
Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder
by: Sandra van Wilpe, et al.
Published: (2020-09-01) -
Progress in the treatment of Bladder Urothelial Carcinoma with PD-1 / PD-L inhibitor
by: Tao Zhang, et al.
Published: (2019-04-01) -
Advisory Council on combined immunochemotherapy for urothelial cancer
by: article Editorial
Published: (2020-11-01) -
Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
by: Faiena I, et al.
Published: (2018-01-01) -
Lactate dehydrogenase: a marker of diminished antitumor immunity
by: Sandra Van Wilpe, et al.
Published: (2020-01-01)